CLYM Company Profile and Key Details

Climb Bio, Inc. (NASDAQ:CLYM) closed at $4.60 USD, losing -$0.30 (-6.12%) from the previous close of $4.90. The stock is currently mid-range between its 52-week high and low $1.05 and $5.05. With a market capitalization of about $313.65 million, Climb Bio, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.05). Key stats such as the average daily volume over the past year has been around 1.27 million shares, in line with its 52-week average. Headquartered in Wellesley Hills, DE, Climb Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Aoife Brennan BCh MMSc, the company employs approximately 17 people and listed since August 10, 2021. Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases.

CLYM has shown sold momentum, gaining 63.33% over the past week and 111.21% over the past quarter, though year-to-date performance is up 172.22%. Short-term trend indicators are bearishly aligned (SMA20 84.07%, SMA50 118.97%, SMA200 185.07%). The stock’s 14-day RSI is 82.18 (overbought), while the ATR of 0.44 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 1.66% below its high and over 366.67% above its low. Average 10-day trading volume of 6.88 million shares is significantly above the 3-month average of 1.24 million, indicating heightened recent market interest.

Climb Bio, Inc. has 67.76 million shares outstanding. The public float is 25.58 million shares, elevated short interest at 3.33% of float. This equals 1.21 million shares. The short ratio is 1.58 days. Institutional investors hold 89.07% of the float. Insiders own 8.19%. RA CAPITAL MANAGEMENT, L.P. holds 3.40 million shares, Brennan Aoife has 48.13 thousand shares and Pimblett Emily has 18.89 thousand shares. Over the past six months, insider transactions show net buying. They sold 20.62 thousand shares across 1 transactions.

Climb Bio, Inc. generated EPS of -$0.75 over the past year. Five-year average earnings growth is -40.44%. Wall Street analysts project EPS growth of 11.57% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $11.00 to $7.00. The high target offers 124.49% upside. The low target suggests 42.86% downside. The mean target is $8.86. This offers 80.82% upside. Climb Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 18.75%. The prior quarter beat by -31.58%. Over the last six quarters, Apple has recorded several small beats. These include -13.33% in March 25, 2025.

Climb Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.80. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Climb Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.06%, with price expected at $5.05 by January 05, 2026, within a range of $4.32 to $5.78 3-Month Outlook: Projected rise of 65.92%, reaching $8.13 by March 20, 2026, with a range of $7.13 to $8.93. 1-Year Outlook: Projected gain of 392.65%, with price at $24.14 by December 22, 2026, within a range of $24.12 to $24.25.

Climb Bio, Inc. (NASDAQ:CLYM) shares are up 172.22% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Climb Bio, Inc. trading at a premium to the broader market with a P/E of -6.66. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.86, suggesting 80.82% upside. Our AI forecast model points to short-term strength (3.06% over two weeks), a medium-term rise (65.92% over three months), and a longer-term gain (392.65% over one year), with expected trading ranges indicating moderate volatility.

Climb Bio, Inc. trades at a P/E ratio of -6.66, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.68 suggesting the stock is closer to book value. The P/FCF stands at -7.91, also above market averages.